Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population
EntityUAM. Departamento de Farmacología
PublisherDove Medical Press Ltd
10.2147/PPA.S93760Patient Preference and Adherence 10 (2016): 1-7
Funded byThe study was funded by Eli & Lilly and Co
SubjectsClinically meaningful outcomes; Oncology; Cost; Cost-effectiveness; Cost-effectiveness threshold; ICER; Spain; Farmacia; Medicina
Rights© 2016 Dilla et al.
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.
Background: In oncology, establishing the value of new cancer treatments is challenging. A clear definition of the different perspectives regarding the drivers of innovation in oncology is required to enable new cancer treatments to be properly rewarded for the value they create. The aim of this study was to analyze the views of oncologists, health care policy makers, patients, and the general population regarding the value of new cancer treatments. Methods: An exploratory and qualitative study was conducted through structured interviews to assess participants’ attitudes toward cost and outcomes of cancer drugs. First, the participants were asked to indicate the minimum survival benefit that a new treatment should have to be funded by the Spanish National Health System (NHS). Second, the participants were requested to state the highest cost that the NHS could afford for a medication that increases a patient’s quality of life (QoL) by twofold with no changes in survival. The responses were used to calculate incremental cost-effectiveness ratios (ICERs). Results: The minimum improvement in patient survival means that justified inclusions into the NHS were 5.7, 8.2, 9.1, and 10.4 months, which implied different ICERs for oncologists (€106,000/quality-adjusted life year [QALY]), patients (€73,520/QALY), the general population (€66,074/QALY), and health care policy makers (€57,471/QALY), respectively. The costs stated in the QoL-enhancing scenario were €33,167, €30,200, €26,000, and €17,040, which resulted in ICERs of €82,917/QALY for patients, €75,500/QALY for the general population, €65,000/QALY for oncologists, and €42,600/QALY for health care policy makers, respectively. Conclusion: All estimated ICER values were higher than the thresholds previously described in the literature. Oncologists most valued gains in survival, whereas patients assigned a higher monetary value to treatments that enhanced QoL. Health care policy makers were less likely to pay more for therapeutic improvements compared to the remaining participants
Google Scholar:Dilla, Tatiana - Lizan, Luís - Paz, Silvia - Garrido, Pilar - Avendaño Solá, Cristina - Cruz-Hernández, Juan J. - Espinosa, Javier - Sacristán, José A.
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design Castaño-Vinyals, Gemma; Aragonés, Nuria; Pérez-Gómez, Beatriz; Martín, Vicente; Llorca, Javier; Moreno, Víctor; Altzibar, Jone M.; Ardanaz, Eva; De Sanjosé, Sílvia; Jiménez-Moleón, José J.; Tardón, Adonina; Alguacil, Juan; Peiró, Rosana; Marcos-Gragera, Rafael; Navarro, Carmen; Pollán Santamaría, Marina Anunciación; Kogevinas, Manolis; Alonso, Maria Teresa; Amiano, Pilar; Arias, Cristina; Azpiri, Mikel; Benavente, Yolanda; Boldo, Elena; Bueno, Aurora; Bustamante, Mariona; Caballero, Francisco Javier; Campo, Elías; Cantón, Rafael; Capelo, Rocío; Carmona, Carme; Casabonne, Delphine; Chirlaque, María Dolores; Cirac, Judith; Clofent, Juan; Colado, Enrique; Costas, Laura; Crous, Marta; Campo, Rosa del; Díaz Santos, Marian; Dierssen-Sotos, Trinidad; Ederra, María; Espinosa, Ana; Fernández Cabrera, Marieta; Fernández Somoano, Ana; Fernández Villa, Tania; García García-Esquinas, Esther; García Martín, Paloma; Gómez-Acebo, Inés; Puga, Cristina González; Gràcia, Esther; Eslava, Marcela Guevara; Guinó, Elisabet; Huerta, José María; Lope, Virginia; López-Abente, Gonzalo; López-Otín, Carlos; Martínez Argüelles, Begoña; Merino Salas, Sergio; Mirón Pozo, Benito; Molina dee La Torre, Antonio José; Moreno, Eduardo; Moreno Iribas, Concepción; Olea, Nicolás; Gelis, Gemma Osca; Paré, Laia; Porta, Miquel; Puig, Montse; Rivad del Fresno, Manuel; Robles, Claudia; Rodríguez Suarez, Marta María; Romero, Beatriz; Sáez Castillo, Ana Isabel; Sala Serra, Maria
ColoLipidGene: Signature of lipid metabolism-related genes to predict prognosis in stage-II colon cancer patients Vargas, Teodoro; Moreno-Rubio, Juan; Herranz Barrera, Jesús; Cejas, Paloma; Molina, Susana; González-Vallinas, Margarita; Mendiola, Marta; Burgos, Emilio; Aguayo, Cristina; Custodio, Ana B.; Machado, Isidro; Ramos, David; Gironella, Meritxell; Espinosa-Salinas, Isabel; Ramos, Ricardo; Martín-Hernández, Roberto; Risueño, Alberto; Las Rivas, Javier de; Reglero Rada, Guillermo J.; Yaya, Ricardo; Fernández-Martos, Carlos; Aparicio, Jorge; Maurel, Joan; Feliú Batlle, Jaime; Ramírez de Molina, Ana